Navigation Links
Prostate Cancer Vaccine Gains FDA Approval
Date:4/29/2010

py or hormone therapy isn't clear, he said.

"There are problems with Provenge," Soloway said. "One is that it's very cumbersome, because patients have to provide their white cells, and I think that's on a regular basis. And two, it's likely to be very expensive." Costs are expected to total $75,000 for the full regimen, experts say.

Soloway agreed that Provenge might also be useful in earlier-stage prostate cancer, but studies are needed to prove that.

However, "once it's approved, it's on the market, and with proper informed consent you can use it for localized [early stage] prostate cancer. Whether insurance companies will pay for it is also not known," Soloway said.

Other new drugs to treat prostate cancer, such as Abiraterone, which prevents the production of the male hormone testosterone, are on the horizon and will compete with Provenge for new treatment regimens, he added.

According to American Cancer Society estimates, more than 192,000 new cases of prostate cancer are diagnosed in the United States each year, and 27,360 men die from the disease.

Prostate cancer is the most common form of cancer diagnosed in American men, after skin cancer. More than 2 million American men who have had prostate cancer at some point are still alive today. The death rate is going down, and the disease is being found earlier, according to the cancer society.

More information

For more on prostate cancer, visit the American Cancer Society.



SOURCES: J. Leonard Lichtenfeld, M.D., deputy chief medical officer, American Cancer Society; Mark Soloway, M.D., professor and chair of urology, University of Miami Miller School of Medicine; April 29, 2010, news release, U.S. Food and Drug Administration


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Prostate Cancer Diagnosis Raises Suicide Risk
2. Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis
3. Loss of gene function makes prostate cancer cells more aggressive
4. Experts Issue Warning on Prostate Hormone Therapy
5. Biochemical profile may help diagnose, determine aggressiveness of prostate cancer
6. New Scan May Help Find Aggressive Prostate Tumors
7. Vaccine approach extends life of metastatic prostate cancer patients
8. Prostate Cancer Care Varies By Hospital Type
9. Study confirms prostate cancer is treated differently at county vs. private hospitals
10. Beer Ingredient Eyed in Prostate Cancer Prevention
11. Race, Weight May Influence Success of Prostate Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... According to Transparency Market Research “Endoscopy ... Analysis and Forecast, 2011 – 2017,” the global endoscopy ... year 2011 and is expected to reach USD 10.8 ... from 2011 to 2017. Flexible endoscopes formed the largest ... 2,201 million for the year 2011. , Related Report ...
(Date:6/19/2013)... Ore. For years, Alzheimer,s researchers have focused on ... with Alzheimer,s and may contribute to the disease: plaques ... another protein, called tau. , But for the first ... the two proteins independently, but at the interaction of ... brain tissue of post-mortem Alzheimer,s patients and in mouse ...
(Date:6/19/2013)... 19, 2013 AquaPrint Solutions in Thomson, IL ... Grub with a newly-designed Harley Davidson motorcycle gas tank. A ... Solutions with an idea of taking a split tank motorcycle ... and transforming it into a work of art. , ... Grub several toilet seats that had been dipped in a ...
(Date:6/19/2013)... 19, 2013 The Cancer Support Community ... of cancer care for the whole patient with the ... Cancer Support Community. This inaugural event, held at the ... MD., Ph.D., recognition of Congress members who have made ... of patients and families currently engaged in the cancer ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 North ... PT continuing education course with an online ... therapy assistants and occupational therapists. , ... course supplemented by an online continuing education ... level algorithmic problem solving skills needed to evaluate ...
Breaking Medicine News(10 mins):Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 2Health News:Endoscopy Devices Market Will Reach USD 10.8 Billion in 2017 : Transparency Market Research 3Health News:New Alzheimer's research suggests possible cause: The interaction of proteins in the brain 2Health News:AquaPrint Solutions Transforms Harley Davidson Gas Tank into a Work Of Art for Poopy’s Pub & Grub 2Health News:Keeping the Promise of Cancer Care for the Whole Patient 2Health News:Keeping the Promise of Cancer Care for the Whole Patient 3Health News:New Evidence Based Information on Treatment for Over 8 Million People in the U.S. Affected With Disorders of the Vestibular System 2
... Nursing (NYUCN) received a four-year, $ 2.8M grant from ... and Infectious Diseases (NIH/NIAID) to study "Combination HIV ... is a collaboration between NYUCN, the University of Nairobi, ... Principal Investigator Ann Kurth notes that HIV ...
... FRIDAY, Oct. 28 (HealthDay News) -- Surgery to remove ... as a thyroidectomy, appears to reduce snoring and other ... study. Researchers compared symptoms in patients with obstructive ... a thyroidectomy. Symptoms of obstructive sleep apnea include snoring, ...
... -- In 2008, as part of a larger initiative aimed ... reimbursing for the treatment of injuries related to in-hospital falls. ... could have an unintended negative consequence. In trying to ... that hospitals might discourage patients from moving about at all. ...
... against a whole range of bacterial pathogens, have been ... drugs to treat viral diseases, on the other hand, ... led by Dr. Albrecht von Brunn of LMU Munich ... have identified a compound that inhibits the replication of ...
... than 1.5 billion overweight adults, including 400 million who are obese. ... women and 60 per cent of men are either overweight or ... weight loss, more than 80 per cent of obese dieters fail ... overweight or obese adults, with a BMI of between 27 and ...
... Trying to avoid eating the entire bag of candy bars ... that you won,t have the willpower to resist midnight raids ... be scary for your diet, according to Kara Smith, special ... several tips on how to limit empty Halloween calories, including: ...
Cached Medicine News:Health News:NYUCN receives $2.8 million NIH/NIAID grant to study combination HIV prevention for Kenyan youth 2Health News:Thyroid Surgery Linked to Improved Sleep Apnea Symptoms 2Health News:Study finds no link between elderly patient activity and hospital falls 2Health News:Novel strategy stymies SARS et al. 2Health News:Novel strategy stymies SARS et al. 3Health News:Obese people regain weight after dieting due to hormones 2
(Date:6/19/2013)... , June 19, 2013   Nektar Therapeutics (Nasdaq: ... a human abuse liability (HAL) study for NKTR-181, ... entry into the brain.  This slow rate of entry is ... abuse of and addiction to current opioid analgesics. 1 ... was rated similar to placebo in "drug liking" and "feeling ...
(Date:6/19/2013)... Calif. , June 19, 2013 BD Biosciences, ... BDX ), a leading global medical technology company, today ... Analyzer , the latest in its line of high-performance research ... Analyzer delivers high-performance multicolor analysis with the most compact footprint ... 73.7 cm) and a height of 30" (76.2 cm). Recognizing ...
(Date:6/19/2013)... , June 19, 2013 NeuroDerm, ... study in volunteers, and preliminary results from a phase ... presented at the 2013 International Congress of Parkinson,s Disease ... drug formula under development for continuous administration through a ... plasma concentrations. ND0612 has been shown in ...
Breaking Medicine Technology:Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6
... 27, 2011 BioDrain Medical, Inc. (OTCBB: BIOR, OTCQB: ... automated surgical fluid disposal, today announced that it has ... underway at surgical facilities in Minnesota.  The Streamway System ... at both sites. Healthcare personnel trained in ...
... BEACH, Fla., June 27, 2011 Implementing an EHR system ... for a doctor that wants to attain Meaningful Use(1), but ... ongoing effort to assist doctors in their migration from paper ... three key services to Medical Messenger customers: ...
Cached Medicine Technology:BioDrain Streamway® System Receives Positive Evaluations on Two Additional Units 2BioDrain Streamway® System Receives Positive Evaluations on Two Additional Units 3Medical Messenger Partners With ComputerAssistant.com to Provide Key Elements of Meaningful Use Success 2
Lumicon 48 mm red filter....
Heavy duty, all purpose illuminator available in blue and green. Unique Clip Switch automatically turns off when returned to pocket. Pre-focused lens tip Heine XHL Halogen bulb for bright, concentra...
... A child-friendly vision test ... takes just seconds. Welch ... first objective, accurate vision ... early detection of refractive ...
... is a black and white ... by people who have visual ... control selector, the Classic can ... black text on a white ...
Medicine Products: